Oseltamivir dosing in premature infants.
We conducted a 2-sample pharmacokinetic study of oseltamivir in 12 premature infants. Oseltamivir 1 mg/kg/dose twice daily in infants <38 weeks postmenstrual age (n=8) resulted in oseltamivir carboxylate exposure comparable to previously published pediatric data, which helps prospectively validate this regimen. Oseltamivir 3 mg/kg/dose once daily in premature infants >38 weeks postmenstrual age (born prematurely but chronologically past term, n=4) resulted in similar oseltamivir and oseltamivir carboxylate exposure. Although these results suggest persistence of immature renal function in this subgroup, further pharmacokinetic/pharmacodynamic description is required to confirm the appropriateness of this regimen.
Department of Pharmacy, St. Louis Children's Hospital, St. Louis, MO 63110, USA. ccm0145@bjc.org
Christopher
C
McPherson
Barbara
B
Warner
David A
DA
Hunstad
Alexis
A
Elward
Edward P
EP
Acosta
D000042:Absorption; D000998:Antiviral Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D019540:Area Under Curve; D004334:Drug Administration Schedule; D006801:Humans; D007231:Infant, Newborn; D007234:Infant, Premature / Q000378:metabolism*; D007668:Kidney / Q000254:growth & development / Q000378:metabolism; D008954:Models, Biological; D053139:Oseltamivir / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D011446:Prospective Studies
D000998:Antiviral Agents; D053139:Oseltamivir